HERA Indicates that Adjuvant Trastuzumab Confers Equal Benefit for HER2-Positive Invasive Ductal and Invasive Lobular Breast Cancers
Journal of Clinical Oncology (JCO) Podcast04/15/13 • 10 min
This Podcast reviews the results of the analysis conducted by Metzger-Filho et al. regarding the benefit of trastuzumab for patients with invasive lobular breast cancer treated on the Herceptin Adjuvant Trial (HERA) and provides perspective regarding the clinical significance of these findings.
04/15/13 • 10 min
Episode Comments
0.0
out of 5
No ratings yet
Join the conversation
Post
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/journal-of-clinical-oncology-jco-podcast-448/hera-indicates-that-adjuvant-trastuzumab-confers-equal-benefit-for-her-65094"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to hera indicates that adjuvant trastuzumab confers equal benefit for her2-positive invasive ductal and invasive lobular breast cancers on goodpods" style="width: 225px" /> </a>
Copy